ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ferric carboxymaltose

Also written as “Ferric Carboxymaltose (FCM)”, “Ferric carboxymaltose” and “Injectafer”.

Its studies are mostly in Anemia, Iron-Deficiency · Anemia · Iron Deficiencies · Restless Legs Syndrome · Heart Failure, led by 4 companies.

Drug pageFerric carboxymaltose: every studyAll 158 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 23, 201346 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daiichi Sankyoits history only280 open or runningphase 4since Sep 23, 2013Apr 20, 2006none ahead
CSLits history only140 open or runningphase 4since Mar 29, 2010Aug 24, 2007none ahead
Sichuan Huiyu Pharmaceutical31 open or runningphase 1since Sep 27, 2023Sep 27, 2023none ahead
Novartisits history only10 open or runningphase 1since Dec 5, 2017Dec 5, 2017none ahead

Also a collaborator on its studies: Suzhou Guochen Biotechnology, Boji Medical Technology, ClinStar, Cytel, Tigermed Consulting, Pierrel Research Europe, ICON Clinical Research, Parexel and SGS.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sichuan Huiyu Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2023First study: phase 1 study in Iron DeficienciesFirst studyNCT06080555 · 84 enrolled · China
  2. Mar 20, 2025Phase 1 study in Healthy AdultNCT06895993 · 84 enrolled · China
  3. May 12, 2026Phase 1 study in Healthy AdultNCT07606105 · 70 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 Sichuan Huiyu Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07606105Healthy Adult · China1RecruitingAug 26, 202670
NCT06895993Healthy Adult · China1CompletedMay 8, 202584
NCT06080555Iron Deficiencies · China1CompletedJan 22, 202484

How it is read

Names in the registry

  • “Ferric Carboxymaltose (FCM)”, 13 entries
  • “Ferric carboxymaltose”, 8 entries
  • “Injectafer”, 5 entries
  • “Ferric Carboxymaltose”, 5 entries
  • “Ferric Carboxymaltose Injection”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.